GeneDx Holdings (WGS) reported adjusted net income Tuesday of $16.8 million compared with an adjusted net loss of $17.8 million a year earlier.
Two analysts surveyed by FactSet expected $1.6 million.
Revenue for the quarter ended Dec. 31 was $95.6 million, up from $58.1 million a year earlier.
Analysts surveyed by FactSet expected $82.2 million.
For the full year, GeneDx expects revenue between $350 million and $360 million, with growth in exome/genome volume and revenue of at least 30%.
Analysts surveyed by FactSet expect $338.8 million.
The company's shares were up more than 25% in recent Tuesday premarket activity.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.